NCT02779257 2022-03-04
Pasireotide Treatment for Neuroendocrine Tumor
University of Maryland, Baltimore
Phase 4 Withdrawn
Clinical Trials
5 trialsNCT03053284 2021-05-14
Pasireotide in Hyperinsulinemic Hypoglycemia
Montefiore Medical Center
Phase 2 Withdrawn
NCT02780882 2018-01-26
SOM230 Ectopic ACTH-producing Tumors
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT01329289 2016-02-12
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 2 Withdrawn
NCT01234974 2013-01-10
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Milton S. Hershey Medical Center
Phase 2 Withdrawn